Gang Han (University of Massachusetts Medical School)
Wen Xue (University of Massachusetts Medical School)
Qiaobing Xu (Tufts University)
This special issue will broadly cover current and emerging gene editing nanotheranostics. Recent advances in gene editing technologies, including the gene editing tools (e.g. CRISPR-Cas9, zinc finger nucleases and TALENs), the delivery and transfection strategies, have enabled us to precisely correct or introduce genetic mutations in eukaryotic cells. Gene editing offers new opportunities for the development of various disease therapeutic approaches as well as for the drug discovery, which attractively holds potentials for clinical translations. In spite of the significant achievements, inappropriate human gene editing may bring severe ethics issues, thus emphasizing the importance of a broadly-agreed ethics regulation.
We therefore intend to highlight this topic in the special issue "Progress in Gene Editing Nanotheranostics". We are highly interested in the following topics but not limited to:
Only review articles will be considered. For more information on the journal and its style, please refer to “Instructions for Authors” at http://thno.org/ms/author. All the invited and contributed manuscripts will undergo the standard peer-review procedure of the Journal “Theranostics”, and will be scrutinized by the guest editor(s) and at least two additional expert reviewers in the field. The deadline for proposal is set for May 30, 2019, the full manuscript submission DEADLINE is set for September 30, 2019 and the first decision will conclude within 6 weeks from submission after peer-review process.
Manuscripts for the special issue should be submitted online at http://www.thno.org/ms/submit (mark "Gene Editing Nanotheranostics Special Issue" in the "Suggested reviewers" field to identify the paper).
All inquiries should be sent to the guest editor(s) at the above email address.